Pediatric Cardiology Fellowship Training Program, Children's Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Heart. 2015 Nov;101(21):1731-7. doi: 10.1136/heartjnl-2015-307930. Epub 2015 Aug 28.
The Fontan circulation is associated with an increased risk of thromboembolic events (TEs). As many as 25% of these thrombotic events result in fatality. More subtle adverse effects on the pulmonary circulation from embolic thrombi may further impair adequate functioning of the circuit. Despite these well-documented phenomena, the most optimal approaches to thromboprophylaxis are still not clearly defined.
A meta-analysis of published trials in English on PubMed and Cochrane libraries that evaluated the role of using TE prophylaxis in patients who underwent the Fontan procedure was conducted.
10 studies with a total number of 1200 patients with an average follow-up time of 7.1 years were identified. A random effect model was used.
The incidence of TE was significantly less in patients who received TE prophylaxis (using either aspirin or warfarin) compared with patients who did not receive TE prophylaxis (OR 0.425, 95% CI 0.194 to 0.929, p<0.01, I(2)=37%). The incidence of TE was significantly lower in patients who received aspirin compared with no TE prophylaxis (OR 0.363, 95% CI 0.177 to 0.744, p<0.01, I(2)=0%) and who received warfarin compared with no TE prophylaxis (OR 0.327, 95% CI 0.168 to 0.634, p<0.01, I(2)=2.5%). There was no significant difference in incidence of TE between warfarin and aspirin (OR 0.936, 95% CI 0.609 to 1.438, p=0.54, I(2)=0%). Furthermore, there was no significant difference in incidence of early TE (within 6 months of the operation) or late TE (>6 months) between patients receiving warfarin and aspirin (OR 0.784, 95% CI 0.310 to 1.982, p=0.37, I(2)=8%) and (OR 0.776, 95% CI 0.249 to 2.42, p=0.3, I(2)=45%), respectively. When only total cavopulmonary connection patients were included, there was again no difference between warfarin and aspirin in the incidence of TE (OR 0.813, 95% CI 0.471 to 1.401, p=0.34, I(2)=11%).
This study shows a significantly lower incidence of TE after Fontan procedure if either aspirin or warfarin is used. This meta-analysis suggests no significant difference in incidence of early or late TE in patients receiving aspirin compared with warfarin.
Fontan 循环与血栓栓塞事件(TE)的风险增加相关。多达 25%的这些血栓事件导致死亡。栓塞性血栓对肺循环的更微妙的不良影响可能进一步损害电路的正常功能。尽管有这些记录在案的现象,但血栓预防的最佳方法仍未明确界定。
对在 PubMed 和 Cochrane 图书馆发表的英文试验进行荟萃分析,评估在 Fontan 手术中使用 TE 预防的作用。
确定了 10 项共纳入 1200 例患者的研究,平均随访时间为 7.1 年。使用随机效应模型。
与未接受 TE 预防的患者相比,接受 TE 预防(使用阿司匹林或华法林)的患者 TE 的发生率显著降低(OR 0.425,95%CI 0.194 至 0.929,p<0.01,I²=37%)。与未接受 TE 预防的患者相比,接受阿司匹林治疗的患者 TE 的发生率显著降低(OR 0.363,95%CI 0.177 至 0.744,p<0.01,I²=0%)和接受华法林治疗的患者(OR 0.327,95%CI 0.168 至 0.634,p<0.01,I²=2.5%)。华法林与阿司匹林治疗的患者 TE 的发生率无显著差异(OR 0.936,95%CI 0.609 至 1.438,p=0.54,I²=0%)。此外,接受华法林和阿司匹林治疗的患者早期 TE(术后 6 个月内)或晚期 TE(>6 个月)的发生率无显著差异(OR 0.784,95%CI 0.310 至 1.982,p=0.37,I²=8%)和(OR 0.776,95%CI 0.249 至 2.42,p=0.3,I²=45%)。当仅纳入全腔静脉肺动脉连接患者时,华法林和阿司匹林治疗的 TE 发生率也无差异(OR 0.813,95%CI 0.471 至 1.401,p=0.34,I²=11%)。
本研究表明,如果使用阿司匹林或华法林,Fontan 手术后 TE 的发生率显著降低。这项荟萃分析表明,接受阿司匹林治疗的患者与接受华法林治疗的患者相比,早期或晚期 TE 的发生率无显著差异。